Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Department of Medical Biology, University of Melbourne, Parkville, Australia.
Sci Adv. 2024 Mar 8;10(10):eadj8803. doi: 10.1126/sciadv.adj8803.
Philadelphia chromosome-positive B cell acute lymphoblastic leukemia (B-ALL), characterized by the fusion gene, remains a poor prognosis cancer needing new therapeutic approaches. Transcriptomic profiling identified up-regulation of oncogenic transcription factors ERG and c-MYC in B-ALL with ERG and c-MYC required for B-ALL in murine and human models. Profiling of ERG- and c-MYC-dependent gene expression and analysis of ChIP-seq data established ERG and c-MYC coordinate a regulatory network in B-ALL that controls expression of genes involved in several biological processes. Prominent was control of ribosome biogenesis, including expression of RNA polymerase I (POL I) subunits, the importance of which was validated by inhibition of cells by POL I inhibitors, including CX-5461, that prevents promoter recruitment and transcription initiation by POL I. Our results reveal an essential ERG- and c-MYC-dependent transcriptional network involved in regulation of metabolic and ribosome biogenesis pathways in B-ALL, from which previously unidentified vulnerabilities and therapeutic targets may emerge.
费城染色体阳性 B 细胞急性淋巴细胞白血病(B-ALL)的特征是融合基因,仍然是一种预后不良的癌症,需要新的治疗方法。转录组谱分析鉴定出致癌转录因子 ERG 和 c-MYC 在 B-ALL 中的上调,在小鼠和人类模型中,ERG 和 c-MYC 是 B-ALL 所必需的。对 ERG-和 c-MYC 依赖性基因表达的分析和 ChIP-seq 数据的分析建立了 ERG 和 c-MYC 在 B-ALL 中协调调控网络,控制参与多个生物学过程的基因表达。突出的是核糖体生物发生的控制,包括 RNA 聚合酶 I(POL I)亚基的表达,这一点通过 POL I 抑制剂抑制细胞得到了验证,POL I 抑制剂包括 CX-5461,可阻止 POL I 的启动子募集和转录起始。我们的结果揭示了在 B-ALL 中调节代谢和核糖体生物发生途径的必需的 ERG 和 c-MYC 依赖性转录网络,从中可能出现以前未识别的脆弱性和治疗靶点。